# Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

> **NCT06779136** · PHASE3 · RECRUITING · sponsor: **Shanghai Mabgeek Biotech.Co.Ltd** · enrollment: 160 (estimated)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06779136
- **Lead sponsor:** Shanghai Mabgeek Biotech.Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-26
- **Primary completion:** 2026-08
- **Final completion:** 2026-11
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06779136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06779136, "Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06779136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*